JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Home・Elenco Azioni・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Chiusa

5.81 -12.37

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

5.71

Massimo

5.91

Metriche Chiave
By Trading Economics
Entrata	453K -27M
Margine di Profitto	-2,027.003
Dipendenti	81
EBITDA	408K -29M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+136.66% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	86M 280M
Apertura precedente	18.18
Chiusura precedente	5.81

Ventyx Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 ott 2025, 18:41 UTC

Utili

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 ott 2025, 18:31 UTC

Utili

Correction to Procter & Gamble to Focus on Innovation

24 ott 2025, 16:25 UTC

I principali Market Mover

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 ott 2025, 21:24 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

24 ott 2025, 21:24 UTC

Discorsi di Mercato

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 ott 2025, 21:07 UTC

Utili

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 ott 2025, 20:58 UTC

Utili

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 ott 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

24 ott 2025, 20:40 UTC

Utili

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 ott 2025, 20:24 UTC

Utili

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 ott 2025, 20:23 UTC

Utili

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 ott 2025, 20:13 UTC

Utili

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 ott 2025, 20:07 UTC

Discorsi di Mercato

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 ott 2025, 19:40 UTC

Discorsi di Mercato

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 ott 2025, 19:35 UTC

Discorsi di Mercato

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 ott 2025, 19:33 UTC

Utili

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 ott 2025, 19:29 UTC

Discorsi di Mercato

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 ott 2025, 18:52 UTC

Utili

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 ott 2025, 18:41 UTC

Utili

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 ott 2025, 18:03 UTC

Utili

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 ott 2025, 18:02 UTC

Utili

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 ott 2025, 18:00 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 ott 2025, 16:57 UTC

Utili

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 ott 2025, 16:54 UTC

Discorsi di Mercato

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 ott 2025, 16:44 UTC

Discorsi di Mercato

Utili

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 ott 2025, 16:39 UTC

Discorsi di Mercato

Utili

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 ott 2025, 16:33 UTC

Utili

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 ott 2025, 16:23 UTC

Utili

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 ott 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

24 ott 2025, 16:07 UTC

Utili

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Ventyx Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

136.66% in crescita

Previsioni per 12 mesi

Media 13.75 USD 136.66%

Alto 21 USD

Basso 9 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Ventyx Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 6 che hanno fornito valutazioni azionarie a Ventyx Biosciences Inc - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.